ISSN 1662-4009 (online)

ey0018.15-3 | (1) | ESPEYB18

15.3. Metabolic effects of late dinner in healthy volunteers - a randomized crossover clinical trial

Gu Chenjuan , Brereton Nga , Schweitzer Amy , Cotter Matthew , Duan Daisy , Borsheim Elisabet , Wolfe Robert R , Pham Luu V , Polotsky Vsevolod Y , Jun Jonathan C

Journal of Clinical Endocrinology & Metabolism, 2020. Vol 105(8), 2789–2802. doi: https://doi.org/10.1210/clinem/dgaa354The authors performed a randomized crossover trial of Late Dinner (22:00 hours) vs Routine Dinner (18:00) in a laboratory setting in 20 healthy adult volunteers. Meal contents and sleep period (23:00-07:00) were kept the same in both arms and sleep patterns were u...

ey0017.10-12 | (1) | ESPEYB17

10.12. Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs

Yu Jicheng , Wang Jinqiang , Zhang Yuqi , Chen Guojun , Mao Weiwei , Ye Yanqi , Kahkoska Anna R , Buse John B , Langer Robert , Gu Zhen

To read the full abstract: Nat Biomed Eng. 2020 May;4(5):499–506. doi: 10.1038/s41551-019-0508-y.Glucose-responsive insulin delivery systems that mimic pancreatic endocrine function could enhance health and improve quality of life for people with type 1 and type 2 diabetes with reduced β-cell function. However, insulin delivery systems with rapid in vivo glucose-respon...

ey0020.8-14 | New Hopes | ESPEYB20

8.14. Glucose-responsive microneedle patch for closed-loop dual-hormone delivery in mice and pigs

C Yang , T Sheng , W Hou , J Zhang , L Cheng , H Wang , W Liu , S Wang , X Yu , Y Zhang , J Yu , Z Gu

Brief summary: In this experimental study, a transdermal polymeric microneedle (MN) patch for glucose-responsive closed-loop insulin and glucagon delivery was developed. In chemically-induced type 1 diabetes (T1D) mouse and minipig models, this glucose-responsive dual-hormone MN patch demonstrated tight regulation in blood glucose.The interplay between insulin and glucagon is essential for blood glucose regulation in individuals with or without diabetes....

ey0018.8-9 | Clinical Trials – New Treatments | ESPEYB18

8.9. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase

R Pivonello , M Fleseriu , J Newell-Price , X Bertagna , J Findling , A Shimatsu , F Gu , R Auchus , R Leelawattana , EJ Lee , JH Kim , A Lacroix , A Laplanche , P O'Connell , L Tauchmanova , AM Pedroncelli , BMK Biller

Lancet Diabetes Endocrinol. 2020; 8(9): 748–761.https://pubmed.ncbi.nlm.nih.gov/32730798/The authors report the outcomes from the pivotal phase 3 trial in patients with Cushing’s disease of osilodrostat (a potent oral inhibitor of cytochrome P450 11B1, [mitochondrial 11β-hydroxylase]). Twice-daily osilodrostat rapidly reduced mean 24-h urine free cortisol (UFC) and sustained ...

ey0015.14-10 | CRISPR-Cas9 gene therapy | ESPEYB15

14.10 Correction of a pathogenic gene mutation in human embryos

H Ma , N Marti-Gutierrez , SW Park , J Wu , Y Lee , K Suzuki , A Koski , D Ji , T Hayama , R Ahmed , H Darby , C Van Dyken , Y Li , E Kang , AR Park , D Kim , ST Kim , J Gong , Y Gu , X Xu , D Battaglia , SA Krieg , DM Lee , DH Wu , DP Wolf , SB Heitner , JCI Belmonte , P Amato , JS Kim , S Kaul , S Mitalipov

To read the full abstract: Nature 2017;548:413-419Over recent years, the Yearbook has followed the rapid advances in CRISPR-Cas9 gene editing technology, initially as a widely adopted research tool, but also as an emerging form of gene therapy. Here, Ma et al. report the first use of CRISPR–Cas9 to efficiently and safely correct a pathogenic heterozygous mutation in human embryos. The...

ey0020.8-10 | New Paradigms | ESPEYB20

8.10. Functional and metabolic alterations of gut microbiota in children with new-onset type 1 diabetes

X Yuan , R Wang , B Han , C Sun , R Chen , H Wei , L Chen , H Du , G Li , Y Yang , X Chen , L Cui , Z Xu , J Fu , J Wu , W Gu , Z Chen , X Fang , H Yang , Z Su , J Wu , Q Li , M Zhang , Y Zhou , L Zhang , G Ji , F Luo

Brief summary: Using in-depth multi-omics analyses of human type 1 diabetes (T1D) samples, the authors profiled gut microbial functional and metabolic alterations. The T1D microbiota showed decreased butyrate production and bile acid metabolism and increased lipopolysaccharide (LPS) biosynthesis. Fecal microbiota transplantation in animal models proved that T1D gut microflora is a causative factor in the regulation of glucose metabolism.The etiology of T...

ey0019.9-1 | Cancer treatment and growth hormone therapy: a consensus | ESPEYB19

9.1. Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement

MCS Boguszewski , CL Boguszewski , W Chemaitilly , LE Cohen , J Gebauer , C Higham , AR Hoffman , M Polak , KCJ Yuen , N Alos , Z Antal , M Bidlingmaier , BMK Biller , G Brabant , CSY Choong , S Cianfarani , PE Clayton , R Coutant , AA Cardoso-Demartini , A Fernandez , A Grimberg , K Guðmundsson , J Guevara-Aguirre , KKY Ho , R Horikawa , AM Isidori , JOL Jorgensen , P Kamenicky , N Karavitaki , JJ Kopchick , M Lodish , X Luo , AI McCormack , L Meacham , S Melmed , Moab S Mostoufi , HL Muller , SJCMM Neggers , Oliveira MH Aguiar , K Ozono , PA Pennisi , V Popovic , S Radovick , L Savendahl , P Touraine , HM van Santen , G Johannsson

n.karavitaki@bham.ac.uk Eur J Endocrinol. 2022; 186: P35-P52. PMID: 35319491.Brief Summary: An international panel of experts produced this consensus statement after critical review of the existing evidence on the safety of GH replacement in cancer and intracranial tumour survivors and in patients with increased cancer risk. Current evidence does not support an association betwe...